Search
Close this search box.

A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

15 October, 2024

Diversity, equity and inclusion at heart of TROG work

15 October 2024: TROG Cancer Research has made a

strategic planning image
1 October, 2024

A plan for the future of cancer research

12 September 2024: TROG Cancer Research has outlined how